KNSA
Kiniksa Pharmaceuticals Ltd
78.80$
+1.0%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +57.0% | +55.0% | +71.7% | -16.2% | +267.5% | -37.6% | -21.9% | +47.8% | -6.2% | +24.4% | -4.2% | +36.0% | +3.3% | +9.2% | +12.4% | +13.8% | +15.3% | +11.8% | +6.0% | +13.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +294.3% | +10.3% | +0.7% | +250.8% | -27.8% | +27.7% | +13.8% | +15.6% | +38.2% | +20.5% | -2.3% | +17.9% | +34.6% | +16.4% | +33.9% | -6.8% | +15.2% | +17.7% | +9.0% | +5.8% | +15.8% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +95.5% | +80.3% | +25.2% | -7.8% | +404.4% | -45.0% | -33.1% | +52.8% | -18.6% | +42.8% | -14.7% | +37.0% | -5.1% | -10.2% | +35.1% | +12.7% | +13.4% | +14.2% | +6.2% | +11.9% | – | |
| – | -82.0% | +194.8% | +51.1% | +113.7% | -57.8% | +36.2% | +20.0% | +75.0% | +64.0% | -47.9% | -28.6% | +4.0% | -8.7% | +6.8% | +40.7% | +19.0% | -24.1% | -17.1% | -19.8% | +45.4% | -25.4% | -34.3% | +21.3% | -11.8% | +3.4% | +57.7% | -28.4% | +17.9% | +32.1% | -8.7% | +9.0% | +34.8% | -45.0% | -3.0% | +28.7% | +43.5% | -20.7% | +48.9% | – | |
| – | -92.1% | +11.4% | +5.7% | +24.1% | +33.5% | +16.6% | +27.5% | +45.3% | +4.8% | +0.6% | -0.1% | +15.0% | -12.5% | +12.4% | +23.7% | +31.4% | +32.9% | +6.1% | -5.0% | +9.5% | -2.3% | +7.3% | +3.5% | +10.3% | +6.7% | +0.4% | +18.1% | +6.6% | +5.3% | +9.6% | +9.4% | -12.6% | +7.4% | +7.7% | +4.8% | +15.6% | +7.7% | +4.4% | – | |
| – | -79.0% | +125.7% | +42.6% | +101.3% | -50.0% | +31.7% | +21.5% | +68.7% | +53.3% | -41.9% | -22.5% | +7.0% | -9.8% | +8.4% | +35.6% | +22.4% | -8.5% | -7.5% | -13.1% | +31.1% | -17.8% | -12.9% | +10.0% | +3.5% | +3.6% | +20.4% | -2.5% | +11.8% | +14.7% | +2.2% | +9.3% | +4.4% | -16.9% | +4.4% | +11.6% | +24.6% | -2.9% | +18.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -87.0% | -285.1% | – | – | – | -20,522.2% | – | – | – | – | +51.9% | +19.2% | -17.7% | +48.1% | -7.1% | – | |
| – | – | – | – | – | – | – | – | +6.5% | +0.0% | -0.2% | -19.6% | -18.5% | -30.2% | -66.3% | -81.6% | -38.8% | -70.0% | -33.3% | -16.7% | +1,440.0% | -55.8% | +202.9% | +212.6% | +146.6% | +130.7% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -85.4% | -236.9% | – | – | – | -682.7% | – | -412.5% | – | – | +47.0% | +18.7% | -14.3% | +40.4% | -4.7% | – | |
| – | -191.7% | – | – | – | -143.1% | – | – | – | -109.9% | – | – | – | -729.8% | – | -88.6% | +18.3% | -73.4% | +382.9% | -111.6% | – | +590.0% | -62.8% | -24,870.7% | – | +22.1% | -657.8% | – | -525.4% | – | +81.2% | -11.6% | -247.3% | – | -28.2% | +72.9% | +4.0% | +11.2% | -43.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -98.0% | -375.1% | – | -192.5% | – | -170.2% | – | – | – | – | +108.8% | +3.4% | -23.0% | +59.1% | +12.6% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -83.4% | -203.9% | – | – | – | -614.1% | – | -348.8% | – | – | +46.0% | +18.5% | -13.8% | +39.7% | -16.5% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.